Background
Lung cancer has the highest incidence of all cancers worldwide [
1]. Due to its aggressive nature, lung cancer is also responsible for a large number of cancer-related mortalities [
2]. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases [
3]. Clinical treatment of NSCLC is challenged by the fact that more than 70% of NSCLC patients are diagnosed at advanced or middle stages, with a low 5-year overall survival rate of less than 15% [
4]. Smoking is closely correlated with NSCLC, while some never-smokers can also develop NSCLC, indicating the important roles of genetic alterations in NSCLC [
5].
Accumulative studies have revealed lncRNAs (> 200 nt) are not “noise” or “background” of the transcriptome [
6]. Instead, lncRNAs have critical functions in diverse cellular processes, including the development of different types of human cancer [
7,
8]. Although lncRNAs do not encode proteins, they regulate the expression of genes at multiple levels, thereby participating in cancer biology [
9]. Regulating the expression of cancer-related lncRNAs provides new insights into the development of cancer therapies [
10]. Decreased expression levels of WT1-AS are closely correlated with the progression of gastric cancer [
11], indicating its tumor-suppressive role in this disease. However, the function of WT1-AS in other types of cancer remains unknown. UCA1 is a well-studied oncogenic lncRNA in many types of cancer including NSCLC [
12]. We performed a whole-genome lncRNAs analysis and found an inverse correlation between WT1-AS and UCA1 in NSCLC (data not shown). Therefore, this study was carried out to investigate the interaction between WT1-AS and UCA1 in NSCLC.
Methods
Patients and specimens
We selected 66 NSCLC patients (40 males and 26 females; 36 to 68 years old; mean age 52.7 ± 6.4 years old) selected from the 178 NSCLC patients admitted by Shenzhen Second People’s Hospital from June 2010 to June 2013. The 66 NSCLC patients included 30 cases of adenocarcinoma, 25 cases of squamous cell carcinoma and 11 cases of large cell carcinoma. All patients were smokers or had a previous history of smoking. No exposure to asbestos and other carcinogens was observed. A family history of lung cancer was not observed. Inclusion criteria: 1) patients received histopathological diagnosis; 2) all patients were newly diagnosed cases; 3) no initiated therapy. Exclusion criteria: 1) patients transferred from another hospital (45 cases excluded); 2) other clinical disorders were diagnosed (64 cases excluded, including 12 cases of heart disease, 26 cases of diabetes, 1 case of skin cancer, 17 cases of severe infection, 2 cases of bone fracture, 1 case of metal disorder, 2 cases of renal injury, 1 case of cystitis, and 2 cases of glaucoma); 3) patients with a history of malignancies (3 cases excluded). Based on clinical findings, the 66 patients included 12, 10, 22 and 22 cases at stage I-IV (AJCC), respectively. Written informed consent was signed by all patients. This study was approved by the Ethics Committee of the aforementioned hospital. Lung biopsy was performed to diagnose NSCLC. During lung biopsy, NSCLC and adjacent normal (non-cancer) tissues were obtained and stored in − 80 °C. All biopsies were completed under the guidance of MRI before the initiation of therapies. All tissue samples were subjected to histopathological exams and all NSCLC tissues contained more than 90% cancer cells and all non-tumor tissues contained less than 2% cancer cells.
A 5-year follow-up
After admission, the 66 NSCLC patients were monitored for 5 years through phone calls and/or outpatient visits every 1–2 months. Patients died of causes unrelated to NSCLC were excluded.
NSCLC cells and transient transfection
Two human NSCLC cell lines H1993 and H1581 (ATCC, USA) were used. RPMI-1640 medium (90%) was mixed with FBS (10%) to grow cells. Cells were grown at 37 °C in an incubator with 95% humidity and 5% CO2. WT1-AS or UCA1 overexpression vector was constructed with pcDNA3 vector (GenePharma, Shanghai, China). At the confluence of 70–90%, H1993, and H1581 cells were harvested and transfected with either 10 nM WT1-AS or UCA1 overexpression vector. Negative control (NC) experiment was performed by transfecting empty vector into the same number of cells. To perform Control (C) cells, cells without transfections were grown until the end of experiments. After cell transfections, cells were cultivated under normal conditions for another 24 h.
RT-qPCR
RNAzol (Sigma-Aldrich, USA) was used for RNA isolation from H1993 and H1581 cells (106 cells) or tissues (about 0.025 g tissues in 0.5 ml RNAzol reagent). DNase I digestion was performed on all RNA samples. Following that, reverse transcriptions were performed to synthesize cDNAs. With cDNAs as a template, qPCRs were performed to detect the expression of WT1-AS and UCA with 18S rRNA as the endogenous control. Three technical replicates were included in each experiment and Ct values of targeted genes were normalized to 18S rRNA using the 2-ΔΔCT method. The primer sequences were: WT1-AS Forward: 5′-GAGGACAGA GAGGCATGGAG-3′; Reverse: 5′-ACCCCTAGGCAAGGAGAAGA-3′; UCA1 Forward: 5′-ACGCTAACTGGCACCTTGTT-3′; Reverse: 5′-TGGGGATTACTGGGGTAGGG-3′; 18S rRNA Forward: 5′-CGGCTACCACATCCAAGGAA-3′; Reverse: 5′-TGTCACTACCTCCCCGTGTCA-3′.
Cell invasion and migration assays
H1993 and H1581 cells were transferred to the upper Transwell chamber (8 μm pore, Corning, Corning, NY) with 3000 cells in 0.1 ml non-serum medium per well. Each cell transfection group included three replicates. The lower Transwell chamber was filled with medium supplemented with 20% FBS. Matrigel (356,234, Millipore, USA)–coated membrane was used in invasion assay, while uncoated membranes were used in migration assay. Cells were cultured under the condition of 37 °C and 5% CO2 for 12 h. After that, upper surface was cleaned, and 0.5% crystal violet (Sigma-Aldrich, USA) was used to stain lower surface at 25 °C for 30 min. An optical microscope was used to observe the stained cells. All groups were normalized to the C group, which was set to “100”.
Cell proliferation assay
Cell count Kit-8 (CCK-8, Sigma-Aldrich) was used to evaluate the effect of overexpression of WT1-AS and UCA1 on proliferation of H1993 and H1581 cells. Briefly, 3× 104 cells were mixed with 1 mL medium. Under the above conditions, cells were grown with a cell culture plate (96 Wells, 0.1 mL per well) at 4 h before the end of cell culture, cck-8 solution (10 μL) was added to each well. Then 10 μL DMSO was added, and OD values at 450 nm were measured.
Western-blot
H1993 and H1581 cells were mixed with RIPA solution (Beyotime) to extract total proteins. The protein concentration was detected by the BCA assay kit (Beyotime). All protein samples were denatured by incubating the samples in boiling water for 15 min. After that, electrophoresis was performed using 10% SDS-PAGE gel to separate protein molecules. After that, proteins were transferred to PVDF membranes, followed by blocking in PBS containing 5% non-fat milk at room temperature for 2 h. After that, membranes were incubated with rabbit primary antibodies of E-cadherin (ab40772, Abcam), vimentin (ab92547, Abcam), p53 (ab131442, Abcam) and β-actin (ab8226, Abcam) at 4 °C for 18 h. After that, membranes were further incubated with IgG-HRP goat anti rabbit (MyBioSource) at 24 °C for 2 h. Signals were developed using ECL (Sigma-Aldrich) and quantity one was used to normalize the signals.
Statistical analysis
Data from at least 3 biological replicates of each experiment were used to calculate mean values. One-sided t test and Chi square test were performed to explore differences between two types of (NSCLC and non-cancer) tissues. ANOVA Tukey’s test was used to compare multiple groups. Correlations were explored using linear regression. Based on WT1-AS expression in NSCLC tissues, 66 NSCLC patients were grouped into low and high WT1-AS level groups, 34 and 32 cases in each group (Youden’s index at the cutoff value), respectively. Survival data of both groups were used to plot survival curves, followed by comparison by log-rank test. p < 0.05 were considered as statistically significant.
Discussion
The role of WT1-AS in NSCLC was investigated in this study. We found that downregulation of WT1-AS in NSCLC was correlated with the poor survival of NSCLC patients. In addition, overexpression of WT1-AS may inhibit NSCLC cell invasion and migration through the downregulation of UCA1.
The progression of NSCLC requires the involvement of lncRNAs [
13]. For instance, lncRNA PVT1 is upregulated in NSCLC and promotes tumorigenesis [
14]. In contrast, lncRNA MEG3 is downregulated in NSCLC and interacts with p53 to induce cancer cell apoptosis and inhibit cancer cell proliferation [
15]. UCA is a well-characterized oncogenic lncRNA in different types of cancer including NSCLC [
12]. Consistently, we also showed that upregulation of UCA1 in NSCLC tissues and its enhancing effects on cancer cell invasion and migration [
12]. Based on our knowledge, the expression pattern of WT1-AS has only been characterized in gastric cancer [
13]. In this study, we found that WT1-AS was downregulated in NSCLC and it inhibited the invasion and migration of cancer cells. Our data suggest that WT1-AS is a tumor suppressor in NSCLC.
Accurate prognosis assignment provided guidance for the determination of treatment strategies and post-treatment care [
16]. This study showed that low expression levels of WT1-AS in NSCLC tissues before therapies predicted the poor survival of NSCLC patients. Therefore, measuring the expression levels of WT1-AS before treatment may assist the prognosis of NSCLC.
LncRNAs play a tumor-suppressive or oncogenic role in cancer biology by regulating downstream cancer-related pathways and other non-coding RNAs, such as miRNAs [
17,
18]. However, the interactions between different lncRNAs have not been well studied. Our study showed that WT1-AS downregulated the expression of UCA1 in NSCLC cells, and decreased cell proliferation and ETM, thereby inhibiting NSCLC cell invasion and migration. Our study provided new insights into the pathogenesis of NSCLC. However, more studies are needed to further investigate the mechanism mediating the interactions between UCA1 and WT1-AS.
It is worth noting that a larger sample size is needed to further improve the authenticity of the conclusions. In this study, our study only included in vitro cell experiments. However, whether these tumors have deletions at the 11p13 chromosomal locus, the potential silencing by epigenetic mechanisms, or possibly some other reasons causing the lower levels of WT1-AS in NSCLC relative to normal lung is still unknown. Therefore, in vivo experiments are needed to test the roles of the interaction between UCA1 and WT1-AS in tumor progression as well as the potential reasons underlying the lower levels of WT1-AS in NSCLC relative to normal lung.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.